A phase 2 study of vatalanib in metastatic melanoma patients

Cook, Natalie, Basu, Bristi, Biswas, Swethajit, Kareclas, Paula, Mann, Colette, Palmer, Cheryl, Thomas, Anne, Nicholson, Steve, Morgan, Bruno, Lomas, David, Sirohi, Bhawna, Mander, Adrian P. ORCID: https://orcid.org/0000-0002-0742-9040, Middleton, Mark and Corrie, Pippa G. 2010. A phase 2 study of vatalanib in metastatic melanoma patients. European Journal of Cancer 46 (15) , pp. 2671-2673. 10.1016/j.ejca.2010.07.014

Full text not available from this repository.

Abstract

Background A phase 2 study of vatalanib (PTK787/ZK222584) an oral tyrosine kinase inhibitor of VEGFR 1, 2 and 3 was undertaken in patients with metastatic melanoma. Methods Adults with pathologically confirmed metastatic melanoma, WHO Performance status 0–2, and adequate haematological, hepatic and renal function, were treated with vatalanib until disease progression. The trial used Fleming’s single stage design. Results Tumour control rate (CR + PR + SD) was 35% at 16 weeks, with objective response seen in only 1 patient. Median progression-free survival was 1.8 months (95% CI 1.8–3.7 months) and median overall survival was 6.5 months (95% CI 3.9–10.2 months). Conclusion Vatalanib stabilised disease in a proportion of patients, although overall survival was disappointing.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Elsevier
ISSN:	0959-8049
Date of Acceptance:	14 July 2010
Last Modified:	04 Nov 2022 12:28
URI:	https://orca.cardiff.ac.uk/id/eprint/123265

Citation Data

Cited 24 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item